90 related articles for article (PubMed ID: 22534465)
21. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
Han A; Xue J; Hu M; Zheng J; Wang X
Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
[TBL] [Abstract][Full Text] [Related]
22. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.
Bhosale P; Peungjesada S; Wei W; Levenback CF; Schmeler K; Rohren E; Macapinlac HA; Iyer RB
Int J Gynecol Cancer; 2010 Aug; 20(6):936-44. PubMed ID: 20683399
[TBL] [Abstract][Full Text] [Related]
23. Performance of integrated FDG-PET/contrast-enhanced CT in the staging and restaging of colorectal cancer: comparison with PET and enhanced CT.
Dirisamer A; Halpern BS; Flöry D; Wolf F; Beheshti M; Mayerhoefer ME; Langsteger W
Eur J Radiol; 2010 Feb; 73(2):324-8. PubMed ID: 19200683
[TBL] [Abstract][Full Text] [Related]
24. Indeterminate pleural metastasis on contrast-enhanced chest CT in non-small cell lung cancer: improved differential diagnosis with (18)F-FDG PET/CT.
Jung MY; Chong A; Seon HJ; Choi S; Kim YH; Shin SS; Kim JW; Bom HS
Ann Nucl Med; 2012 May; 26(4):327-36. PubMed ID: 22350956
[TBL] [Abstract][Full Text] [Related]
25. Value of fusion of PET and MRI in the detection of intra-pelvic recurrence of gynecological tumor: comparison with 18F-FDG contrast-enhanced PET/CT and pelvic MRI.
Kitajima K; Suenaga Y; Ueno Y; Kanda T; Maeda T; Makihara N; Ebina Y; Yamada H; Takahashi S; Sugimura K
Ann Nucl Med; 2014 Jan; 28(1):25-32. PubMed ID: 24129541
[TBL] [Abstract][Full Text] [Related]
26. Combined positron emission tomography-computed tomography and tumor markers for detecting recurrent ovarian cancer.
Pan HS; Lee SL; Huang LW; Chen YK
Arch Gynecol Obstet; 2011 Feb; 283(2):335-41. PubMed ID: 20221620
[TBL] [Abstract][Full Text] [Related]
27. PET/CT scanning guided intensity-modulated radiotherapy in treatment of recurrent ovarian cancer.
Du XL; Jiang T; Sheng XG; Li QS; Wang C; Yu H
Eur J Radiol; 2012 Nov; 81(11):3551-6. PubMed ID: 22521528
[TBL] [Abstract][Full Text] [Related]
28. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.
Sari O; Kaya B; Kara PO; Gedik GK; Celik C; Ozbek O; Serdengecti M
Rev Esp Med Nucl Imagen Mol; 2012; 31(1):3-8. PubMed ID: 21549452
[TBL] [Abstract][Full Text] [Related]
29. Preoperative nodal staging of uterine cancer: is contrast-enhanced PET/CT more accurate than non-enhanced PET/CT or enhanced CT alone?
Kitajima K; Suzuki K; Senda M; Kita M; Nakamoto Y; Sakamoto S; Onishi Y; Maeda T; Yoshikawa T; Ohno Y; Suganuma N; Sugimura K
Ann Nucl Med; 2011 Aug; 25(7):511-9. PubMed ID: 21670955
[TBL] [Abstract][Full Text] [Related]
30. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings.
Chung HH; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):480-6. PubMed ID: 17089122
[TBL] [Abstract][Full Text] [Related]
31. Is contrast material needed after treatment of malignant lymphoma in positron emission tomography/computed tomography?
Nakamoto Y; Nogami M; Sugihara R; Sugimura K; Senda M; Togashi K
Ann Nucl Med; 2011 Feb; 25(2):93-9. PubMed ID: 20957527
[TBL] [Abstract][Full Text] [Related]
32. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
Rayamajhi S; Balachandran A; Katz M; Reddy A; Rohren E; Bhosale P
Abdom Radiol (NY); 2018 Feb; 43(2):505-513. PubMed ID: 28900703
[TBL] [Abstract][Full Text] [Related]
33. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.
Hildebrandt MG; Gerke O; Baun C; Falch K; Hansen JA; Farahani ZA; Petersen H; Larsen LB; Duvnjak S; Buskevica I; Bektas S; Søe K; Jylling AM; Ewertz M; Alavi A; Høilund-Carlsen PF
J Clin Oncol; 2016 Jun; 34(16):1889-97. PubMed ID: 27001573
[TBL] [Abstract][Full Text] [Related]
34. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT.
Kitajima K; Murakami K; Yamasaki E; Domeki Y; Kaji Y; Fukasawa I; Inaba N; Suganuma N; Sugimura K
Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1439-48. PubMed ID: 18418592
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic performance of 18F-FDG PET/contrast-enhanced CT versus contrast-enhanced CT alone for post-treatment detection of ovarian malignancy.
Tawakol A; Abdelhafez YG; Osama A; Hamada E; El Refaei S
Nucl Med Commun; 2016 May; 37(5):453-60. PubMed ID: 26745811
[TBL] [Abstract][Full Text] [Related]
36. ¹⁸F-FDG PET/contrast enhanced CT in the standard surveillance of high risk colorectal cancer patients.
Jiménez Londoño GA; García Vicente AM; Sánchez Pérez V; Jiménez Aragón F; León Martin A; Cano Cano JM; Domínguez Ferreras E; Gómez López OV; Espinosa Arranz J; Soriano Castrejón ÁM
Eur J Radiol; 2014 Dec; 83(12):2224-2230. PubMed ID: 25306106
[TBL] [Abstract][Full Text] [Related]
37. Use of full-dose contrast-enhanced CT for extrahepatic staging using Gallium-68-DOTATATE PET/CT in patients with neuroendocrine tumors.
Apitzsch J; Verburg FA; Mottaghy F; Heinzel A
Diagn Interv Radiol; 2021 Jul; 27(4):573-579. PubMed ID: 34313245
[TBL] [Abstract][Full Text] [Related]
38. Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence.
Sironi S; Picchio M; Landoni C; Galimberti S; Signorelli M; Bettinardi V; Perego P; Mangioni C; Messa C; Fazio F
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):472-9. PubMed ID: 17106701
[TBL] [Abstract][Full Text] [Related]
39. Carbon-11-acetate positron emission tomography (PET), versus fluorine- 18 fluorodeoxyglucose PET and CT for the diagnosis of recurrent prostate cancer after radical prostatectomy in cases of prostate specific antigen of more than 1 to 3ng/mL.
Oyama N; Ito H; Aoki Y; Miwa Y; Akino H; Kudo T; Okazawa H; Fujibayashi Y; Welch M; Yokoyama O
Hell J Nucl Med; 2013; 16(2):146-7. PubMed ID: 24032176
[No Abstract] [Full Text] [Related]
40. JOURNAL CLUB: CT dose optimization for whole-body PET/CT examinations.
Tonkopi E; Ross AA; MacDonald A
AJR Am J Roentgenol; 2013 Aug; 201(2):257-63. PubMed ID: 23883207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]